
Understand how symptoms and repeat testing guide low testosterone assessment alongside weight, sleep, acute illness and medicines.

Functional hypogonadism is reduced testosterone production associated with other health conditions or medicines being taken. The European Association of Urology (EAU) says this diagnosis applies only after organic causes have been ruled out. In other words, a clinician must investigate the cause rather than assume that weight or medication explains a low result.
This article is for informational purposes and is not medical advice. A qualified clinician should assess personal symptoms and test results or make treatment decisions.
The EAU uses total testosterone below 12 nmol/L as a threshold for repeat testing. Its guidance also identifies 12 nmol/L as a reliable diagnostic threshold for late-onset hypogonadism. This is an EAU benchmark, not a universal normal range or a treatment target.
The measurement describes the concentration of testosterone in the tested sample. It does not identify why production may be impaired or whether a reported symptom comes from that finding. That distinction is why a low value and a diagnosis are not interchangeable.
For diagnosis and treatment assessment, the EAU calls for:
These requirements connect the lab finding with the clinical picture. A reading below the threshold starts further evaluation rather than deciding the duration of treatment.
Understanding why test timing and repeat confirmation matter helps keep the reference number in perspective. The question is not simply whether a result crosses a line. It is whether the finding is consistent and fits the person being assessed.
For adult men, the EAU bases diagnosis on compatible symptoms or signs together with consistently low testosterone. Symptoms are therefore part of the assessment, not an optional detail added after a laboratory label.
Yet a laboratory result cannot show how a man feels. Equally, having symptoms does not establish their hormonal cause. A clinician needs to consider both the complaint and the conditions under which testosterone was measured.
The broader history should include recent illness and disrupted sleep. Weight changes and existing health conditions also deserve discussion, along with current medicines. These details help frame the evaluation without turning a possible contributor into a diagnosis.
An assessment should not dismiss a man's concerns because he has obesity or uses a potentially interfering medicine. Nor should it assume that testosterone explains every concern just because a value is low. The EAU's symptom-plus-testing approach keeps both assumptions in check.
Testostra's guide to considering symptoms alongside laboratory evidence develops this distinction.
The EAU recommends assessing other health conditions and potentially interfering drugs before testosterone therapy where appropriate. That is a broader evaluation, not a rule that every man must complete the same lifestyle programme. The following factors have different kinds of supporting evidence.
The EAU identifies obesity and other coexisting conditions as major factors associated with functional hypogonadism. It also says low testosterone is common in men with obesity. An association describes conditions occurring together; it does not prove that obesity is the sole cause of an individual's result or symptoms.
For overweight or obese men with hypogonadism, the EAU recommends weight loss and lifestyle changes as the first approach. Its evidence summary describes the average testosterone improvement from low-calorie dieting and regular physical activity as small. The increase is associated with the amount of weight lost.
This is a measured expectation, not a promise that weight loss will restore a normal result. It also does not mean weight loss is an absolute requirement before any man can receive testosterone therapy. The individual assessment remains important.
A useful discussion is what addressing weight or another health condition could accomplish in the overall evaluation. More background on weight-related hormone findings can help separate that question from claims of a predictable hormonal response.
In a summary of a small sleep-laboratory study, 10 healthy young men had lower average daytime testosterone after a week of restricted sleep. Average levels were about 16.5 nmol/L after restricted sleep versus 18.4 nmol/L in the rested condition.
A separate summary of a 2021 systematic review and meta-analysis reported a different distinction. Total sleep deprivation reduced testosterone, while short-term partial sleep restriction did not produce a statistically significant pooled effect.
These results should be read together. The laboratory experiment was small and short, which limits its application to men in different circumstances. The pooled finding means the evidence does not support assuming that any period of short sleep causes clinically significant hypogonadism.
Sleep disruption is still useful information for the clinical history. It is not a way to calculate how much an individual's testosterone should fall or to decide that treatment is unnecessary. The practical question is how the sleep history fits the symptoms and the testing circumstances.
The EAU says acute disease can be associated with functional hypogonadism and advises against testosterone measurement during acute illness. It also states that testosterone's role in acute illness remains unclear.
A result obtained while someone is acutely unwell should therefore be discussed in that context. It is not proof that the result will return to normal. Nor does it remove the need to assess symptoms and confirm low measurements appropriately.
Useful information for the clinician includes whether an acute illness was present around the blood draw. The clinician can then consider when a measurement would be suitable within the wider evaluation.
You do not need to assign the illness a hormonal explanation before raising it. Reporting the circumstances is more useful than deciding in advance that the low result is either permanent or temporary.
The EAU lists opiates and glucocorticoids among drug groups that may interfere with testosterone regulation. Its guidance calls for reviewing medicines and substances that may affect testosterone production or action.
The point of the review is to identify a possible contributor. A medicine's presence on that list does not establish that it caused a particular man's low testosterone. The prescriber must consider the treatment and the wider clinical picture.
When possible, the EAU recommends addressing interfering drugs before testosterone therapy. This is a recommendation for clinical review, not permission to stop or alter a prescription without advice.
A useful consultation question is whether any current medicine could affect the result and whether that changes the evaluation. Any decision about changing a prescribed treatment belongs with the clinician responsible for that care.
Taken together, these factors explain why one low measurement does not determine a lifelong treatment plan. The EAU supports addressing relevant coexisting conditions and potentially interfering medicines before testosterone therapy where appropriate. It still requires a clinical assessment rather than assuming that every low result is temporary or that therapy is never appropriate.
That makes the sequence important: establish whether low testosterone is consistent, assess possible causes and discuss the relevant health context. The purpose is not to delay care by assigning blame to lifestyle. It is to make the treatment conversation match the finding being investigated.
Ask: “Do my symptoms and repeat morning fasting results support hypogonadism? Have organic causes been assessed? Could weight, sleep, recent illness or medicines be relevant? What should be addressed before discussing testosterone therapy?”
Deciding whether a low result warrants repeat testing or assessment of contributing health factors belongs in clinical care; Testostra explains the evidence behind those questions. Men uncertain about symptoms and their possible causes can use its coverage to better understand hormone findings without treating general information as an individual diagnosis.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra